Table 1.
Baseline patients’ characteristics
| All patientsa (n = 280) no. (%) | No cardiac biomarkers elevation (n = 221) no. (%) | Any cardiac biomarkers elevationb (n = 59) no. (%) | P value | |
|---|---|---|---|---|
| Age at diagnosis, median (range) | 50 (25–75) | 49 (25–75) | 58 (28–73) | < 0.001 |
| BMI (kg/m2), median (range) | 24.9 (16.6–47.6) | 24.7 (16.6–47.6) | 25.9 (18.2–42.6) | 0.185 |
| Diabetes | ||||
| Yes | 9 (3) | 8 (4) | 1 (2) | 0.456 |
| No | 271 (97) | 213 (96) | 58 (98) | |
| Hypertension | ||||
| Yes | 57 (20) | 34 (15) | 23 (39) | < 0.001 |
| No | 223 (80) | 187 (85) | 36 (61) | |
| Ethnicity | ||||
| White | 177 (63) | 127 (57) | 50 (85) | 0.002 |
| Black | 4 (1) | 4 (2) | 0 (0) | |
| Asian | 75 (27) | 69 (31) | 6 (10) | |
| Other | 24 (9) | 21 (10) | 3 (5) | |
| Radiotherapy | 0.763 | |||
| Yes | 199 (71) | 158 (71) | 41 (69) | |
| No | 81 (29) | 63 (29) | 18 (31) | |
| Histology | 0.318 | |||
| Ductal carcinoma | 143 (51) | 112 (51) | 31 (53) | |
| lobular carcinoma | 7 (3) | 4 (2) | 3 (5) | |
| Others/missing | 130 (46) | 105 (47) | 25 (42) | |
| Tumour size (cm): | 0.158 | |||
| ≤ 2 | 0 (0) | 0 (0) | (0) | |
| > 2/≤ 5 | 148 (53) | 112 (51) | 36 (61) | |
| > 5 | 132 (47) | 109 (49) | 23 (39) | |
| Nodal status | 0.718 | |||
| N0/N1 | 228 (81) | 179 (81) | 49 (83) | |
| N2/N3 or missing | 52 (19) | 42 (19) | 10 (17) | |
| Hormone receptor status | 0.088 | |||
| ER and/or PR positive | 148 (53) | 111 (50) | 37 (63) | |
| ER and PR negative | 132 (47) | 110 (50) | 22 (37) | |
| Cardiac events | 10 | 9 | 1 | – |
a
All patients with any troponin T and NT-proBNP measurement at baseline
b
At baseline, week 2, and/or pre-surgery
BMI bodymass index, NT-proBNP amino-terminal fragment of brain natriuretic peptide, ER estrogene receptor, PR progesterone receptor